EUVIMEDEUVIMED entdecken
Open Access

Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier, and distribution to tumor cells in HER2+ brain metastasis model systems

Imran Khan iD, Dinesh Kumar, Wei Zhang, Simone Difilippantonio, Christina Robinson, Debbie Wei, Stanley Lipkowitz iD, Ross Lake iD, Ronald Fleming, Patricia S Steeg

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noag002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Imran Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Blood-Brain Barrier, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CRADA, Collaborative Research and Development Agreement, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractAbstract Background Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) approved for metastatic HER2+ and HER2-low/ultralow breast cancer. It has shown impressive clinical activity for HER2+ brain metastases. We conducted preclinical brain metastasis experiments to understand T-DXd efficacy.

Methods

Nude mice were intracardially injected with either JIMT1-BR (HER2-2+) or SUM190-BR (HER2-3+) brain-tropic breast cancer cells and dosed with 3 or 10 mg/kg T-DXd or 10 mg/kg control-ADC, with endpoints of metastasis number and size, in both the metastasis prevention and treatment of established disease settings.

Results

In the JIMT1-BR model, T-DXd at both doses reduced metastasis number by 48% to 88% and size by 32% to 88%; a reduction of HER2 expression by lesions remaining at the experimental endpoint and heterogeneous T-DXd distribution were observed. A distinct dose effect was observed in SUM190-BR with the 3 mg/kg dose inhibiting size and number by 24% to 39% and 10 mg/kg by 72% to 79%; HER2 expression was maintained together with heterogeneous T-DXd distribution. In both models widespread reduced tumor Ki-67 was observed, while increased cleaved caspase-3 primarily costained with T-DXd. We used an in vitro model of the blood-brain and blood-tumor barriers (BBB/BTB) to ask how T-DXd crossed. Data demonstrated T-DXd endocytosis and transcytosis of brain endothelial cells partially reliant on the neonatal Fc receptor (FcRn). BTB transcytosis was accompanied by increased endothelial RAB11FIP5 expression in vitro and in vivo.

Conclusions

The data confirm T-DXd activity in HER2+ brain metastases and identify important correlates, including heterogeneous uptake, variable HER2 expression at endpoint, tumor cell cytotoxicity, decreased proliferation, and BTB transcytosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsBlood-Brain BarrierErb-b2 Receptor Tyrosine KinasesTrastuzumabImmunoconjugatesReceptors, FcHistocompatibility Antigens Class IBreast NeoplasmsAntineoplastic Agents, ImmunologicalAnimalsFemaleMiceHumansMice, NudeXenograft Model Antitumor AssaysCamptothecin

Stichwörter der Autor:innen

HER2+antibody-drug conjugate (ADC)blood-brain barrierblood-tumor barrierbrain metastasisbreast cancerneonatal Fc receptor (FcRn)trastuzumab deruxtecan

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabImmunoconjugatesFc receptor, neonatalReceptors, FcHistocompatibility Antigens Class Itrastuzumab deruxtecanERBB2 protein, humanAntineoplastic Agents, ImmunologicalCamptothecin

Autor:innen und Institutionen

  • Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Animal Research Technical Support, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
  • Laboratory of Cancer Biology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.

ORCID-Profile: Imran Khan, Stanley Lipkowitz, Ross Lake

Förderung

  • CRADA
  • Collaborative Research and Development Agreement
  • AstraZeneca
  • NCI NIH HHS
  • NIH HHS
  • NIH
  • U.S. Department of Health and Human Services
  • National Cancer Institute

Zitieren

APA

Khan, I., Kumar, D., Zhang, W., Difilippantonio, S., Robinson, C., Wei, D., Lipkowitz, S., Lake, R., Fleming, R., & Steeg, P. S. (2026). Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier, and distribution to tumor cells in HER2+ brain metastasis model systems. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag002

Vancouver

Khan I, Kumar D, Zhang W, Difilippantonio S, Robinson C, Wei D, et al. Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier, and distribution to tumor cells in HER2+ brain metastasis model systems. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag002

BibTeX
@article{Khan2026,
  author = {Khan, Imran and Kumar, Dinesh and Zhang, Wei and Difilippantonio, Simone and Robinson, Christina and Wei, Debbie and Lipkowitz, Stanley and Lake, Ross and Fleming, Ronald and Steeg, Patricia S},
  title = {Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier, and distribution to tumor cells in HER2+ brain metastasis model systems},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noag002}
}
Kostenlos starten →